Summit Therapeutics Inc.
SMMT
$18.91
-$1.55-7.58%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 99.99% | 119.53% | 61.73% | 29.71% | 13.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 68.73% | 85.32% | 88.59% | 93.82% | 93.06% |
| Total Operating Expenses | 137.78% | 176.72% | 130.70% | 93.34% | 35.29% |
| Operating Income | -137.78% | -176.72% | -131.52% | -94.83% | -36.76% |
| Income Before Tax | 64.01% | 67.09% | 72.95% | 80.65% | -680.54% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 64.01% | 67.09% | 72.95% | 80.65% | -680.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 64.01% | 67.09% | 72.95% | 80.65% | -680.54% |
| EBIT | -137.78% | -176.72% | -131.52% | -94.83% | -36.76% |
| EBITDA | -138.21% | -178.58% | -134.18% | -98.08% | -39.16% |
| EPS Basic | 80.00% | 82.21% | 86.23% | 90.88% | -156.16% |
| Normalized Basic EPS | -78.39% | -67.86% | 21.43% | 59.86% | 72.03% |
| EPS Diluted | 79.10% | 81.76% | 85.96% | 90.89% | -155.40% |
| Normalized Diluted EPS | -78.39% | -67.86% | 21.43% | 59.86% | 72.03% |
| Average Basic Shares Outstanding | 16.15% | 38.50% | 87.31% | 210.49% | 298.42% |
| Average Diluted Shares Outstanding | 16.15% | 38.50% | 87.31% | 210.49% | 298.42% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
